FINWIRES · TerminalLIVE
FINWIRES

Zenith Energy Secures Funds via Private Placements, Convertible Loan Facility

By

-- Zenith Energy (ZENA.OL, ZEN.L) said Tuesday it raised funds through private placement offers in the UK and Norway, settled debt, and secured a convertible loan facility.

The energy company noted that it raised 35,653,000 Norwegian kroner from its offering of 40,979,839 shares in Norway, and 250,000 pounds sterling from selling 3,629,764 shares in the UK. Additionally, it issued 20,964,527 shares to settle its debt worth 18.2 million kroner.

Admission of the shares on the London bourse's main market is expected on May 5. Meanwhile, the 12-month loan facility will be worth up to 2 million pounds and have a 5% yearly interest rate, with a repayment date of April 27, 2027.

Proceeds were earmarked for its subsidiaries' international arbitration proceedings, the expansion of its solar energy portfolio, its environmental impact assessments, potential investments, and general working capital.

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS